Changing need for bioanalysis during drug development
- 15 October 2007
- journal article
- review article
- Published by Wiley in Biomedical Chromatography
- Vol. 22 (3) , 235-243
Abstract
Recent years have witnessed the introduction of several high‐quality review articles into the literature covering various scientific and technical aspects of bioanalysis, including chirality aspects. Now it is widely accepted that bioanalysis is an integral part of the pharmacokinetic/pharmacodynamic characterization of a novel chemical entity (NCE) from the time of its discovery and during various stages of drug development leading to its market authorization. There is a need for a comprehensive review article that takes into account the changing faces of bioanalysis from the time of inception of an NCE at the discovery stage and as the NCE moves forward in development. This review attempts to cover the versatility in the applicability of bioanalytical aspects with respect to the nature, rigor and available choices of analyses. For ease of understanding, bioanalytical aspects are discussed under sections covering discovery, preclinical and clinical stages. It is intended to give some general thoughts in this area which will form basis of a general framework as to how one would approach bioanalysis from inception (i.e. discovery of a lead molecule) and progressing through various stages of drug development. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 43 references indexed in Scilit:
- Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometryRapid Communications in Mass Spectrometry, 2007
- Integration of Atazanavir into an Existing Liquid Chromatography UV Method for Protease Inhibitors: Validation and ApplicationTherapeutic Drug Monitoring, 2007
- An improved high‐throughput liquid chromatographic/tandem mass spectrometric method for terbinafine quantification in human plasma, using automated liquid–liquid extraction based on 96‐well format platesBiomedical Chromatography, 2007
- Stereoselective pharmacokinetics of oxybutynin andN-desethyloxybutyninin vitroandin vivoXenobiotica, 2007
- Therapeutic Drug Monitoring of Mirtazapine, Desmethylmirtazapine, 8-Hydroxymirtazapine, and Mirtazapine-N-oxide by Enantioselective HPLC With Fluorescence DetectionTherapeutic Drug Monitoring, 2006
- Drug disposition of chiral and achiral drug substrates metabolized by cytochrome P450 2D6 isozyme: case studies, analytical perspectives and developmental implicationsBiomedical Chromatography, 2006
- High‐performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of rat in situ intestinal permeability studies using timed wavelength detectionBiomedical Chromatography, 2005
- Review on the chemical and thermal stability of stationary phases for reversed-phase liquid chromatographyJournal of Chromatography A, 2004
- Simultaneous chiral analyses of multiple analytes: case studies, implications and method development considerationsBiomedical Chromatography, 2004
- Liquid chromatography coupled with inductively coupled plasma mass spectrometry in the pharmaceutical industry: selected examplesJournal of Chromatography A, 2004